Table 1 Distribution of SCCmec types according to antibiotic non-susceptibility phenotypes for MRSA isolates (n = 2019)
Antibiotic non-susceptibility phenotype | SCCmec type | |||||||
|---|---|---|---|---|---|---|---|---|
I | II | III | IV | V | VI | Untypeable | Negative | |
Erythromycin | 0 | 133 (6.58%) | 920 (45.56%) | 391 (19.36%) | 4 (0.19%) | 2 (0.09%) | 249 (12.33%) | 2 (0.09%) |
Clindamycin | 1 (0.04%) | 129 (6.38%) | 106 (5.25%) | 31 (1.53%) | 0 | 4 (0.19%) | 30 (1.48%) | 0 |
Oxacillin | 2 (0.09%) | 135 (6.68%) | 916 (45.36%) | 648 (32.09%) | 7 (0.34%) | 9 (0.44%) | 271 (13.42%) | 2 (0.09%) |
Penicillin | 2 (0.09%) | 138 (6.83%) | 926 (45.86%) | 651 (32.24%) | 7 (0.34%) | 9 (0.44%) | 274 (13.57%) | 2 (0.09%) |
Trimethoprim/Sulfamethoxazole | 0 | 12 (0.59%) | 883 (43.73%) | 542 (26.84%) | 2 (0.09%) | 3 (0.14%) | 42 (2.08%) | 2 (0.09%) |
Daptomycin | 0 | 0 | 7 (0.34%) | 2 (0.09%) | 0 | 0 | 2 (0.09%) | 0 |
Linezolid | 0 | 3 (0.14%) | 3 (0.14%) | 3 (0.14%) | 0 | 0 | 3 (0.14%) | 0 |
Tetracycline | 0 | 14 (0.69%) | 913 (45.22%) | 573 (28.38%) | 3 (0.14%) | 2 (0.09%) | 79 (3.91%) | 2 (0.09%) |
Rifampin | 0 | 14 (0.69%) | 62 (3.07%) | 571 (28.28%) | 1 (0.04%) | 2 (0.09%) | 19 (0.94%) | 2 (0.09%) |
Ciprofloxacin | 0 | 134 (6.63%) | 917 (45.41%) | 589 (29.17%) | 4 (0.19%) | 3 (0.14%) | 76 (3.76%) | 2 (0.09%) |
Levofloxacin | 0 | 134 (6.63%) | 916 (45.36%) | 512 (25.35%) | 3 (0.14%) | 3 (0.14%) | 75 (3.71%) | 2 (0.09%) |
Moxyfloxacin | 0 | 133 (6.58%) | 918 (45.46%) | 510 (25.26%) | 3 (0.14%) | 2 (0.09%) | 75 (3.71%) | 2 (0.09%) |
Gentamicin | 0 | 19 (0.94%) | 912 (45.17%) | 556 (27.53%) | 6 (0.29%) | 3 (0.14%) | 242 (11.98%) | 2 (0.09%) |